 |
6 Diseases |  |
0 Trials |
|
0 Trials |  |
25 News |  |
- Efficacy and Safety of Glucagon-Like Peptide 1 Analogs and Agonists (aGLP1) in Overweight/Obese Patients: a Systematic Review and an Updated Network Meta-Analysis (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_1868;
Tirzepatide 15 mg appears to be the most effective aGLP1 for weight reduction while it is similar to other aGLP1 regarding acceptability and safety. Taspoglutide was remarkably inferior to other aGLP1 considering discontinuation risk.
- | taspoglutide (BIM51077) / Ipsen
Journal: Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes. (Pubmed Central) - Feb 9, 2022
Here, we report cryoelectron microscopy (cryo-EM) structures and cryo-EM 3D variability analysis of semaglutide- and taspoglutide-bound GLP-1R-Gs protein complexes. These reveal similar peptide interactions to GLP-1 but different motions within the receptor and bound peptides, providing insights into the molecular determinants of GLP-1R peptide engagement.
- ||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Clinical, Retrospective data, Review, Journal, Adverse events: Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis. (Pubmed Central) - Dec 10, 2021
These reveal similar peptide interactions to GLP-1 but different motions within the receptor and bound peptides, providing insights into the molecular determinants of GLP-1R peptide engagement. Direct meta-analysis showed significant WLOP with: -1.44kg (95% CI, -2.14 to -0.74) with dulaglutide ≥1.5 mg; -1.82kg (-2.42 to -1.23) with exenatide immediate release (IR); -2.20kg (-4.31 to -0.08) with exenatide extended release (ER); -3.20kg (-6.53 to 0.15) with efpeglenatide; -2.72kg (-3.35 to -2.09) with liraglutide ≤1.8mg; -4.49kg (-5.26 to -3.72) with liraglutide >1.8mg; -0.62kg (-1.22 to -0.02) with lixisenatide; -4.33kg (-5.71 to -3.00) with semaglutide SQ 50%) in WL and AEs reflected magnitude, not direction of effect.
- || simvastatin / Generic mfg., taspoglutide (BIM51077) / Roche
P1 data, Journal: Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials. (Pubmed Central) - Sep 5, 2020
Overall, multiple doses of taspoglutide did not result in changes in the pharmacokinetics of digoxin, an oral contraceptive containing ethinylestradiol and levonorgestrel, lisinopril, warfarin, and simvastatin that would be considered of clinical relevance. Therefore, no dose adjustments are warranted upon co-administration.
- | Symlin (pramlintide) / AstraZeneca, taspoglutide (ITM-077) / Teijin, taspoglutide (BIM51077) / Roche
Journal: PEGylated prodrugs of antidiabetic peptides amylin and GLP-1. (Pubmed Central) - Oct 27, 2019
Thus, taspoglutide was released even after an incubation period of 24 h in serum with the content of degraded taspoglutide being below 2% in the prodrug at this time point. This PEG-prodrug technology could provide precisely tuned long-acting anti-diabetic and anti-obesity therapies and even once-monthly administration intervals when combined with other formulation strategies.
- |||| taspoglutide (BIM51077) / Ipsen
Trial primary completion date, Monotherapy: A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy (clinicaltrials.gov) - Jul 28, 2016
P3, N=305, Completed, Sponsor: Hoffmann-La Roche
This PEG-prodrug technology could provide precisely tuned long-acting anti-diabetic and anti-obesity therapies and even once-monthly administration intervals when combined with other formulation strategies. Trial primary completion date: Jan 2011 --> May 2010
- |||| taspoglutide (BIM51077) / Ipsen
Trial primary completion date, Combination therapy: A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea. (clinicaltrials.gov) - Jul 28, 2016
P3, N=1072, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jan 2011 --> May 2010 Trial primary completion date: Mar 2011 --> Dec 2010
- |||| taspoglutide (BIM51077) / Ipsen
Trial primary completion date: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise. (clinicaltrials.gov) - Jul 28, 2016
P3, N=373, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2011 --> Dec 2010 Trial primary completion date: Mar 2011 --> Apr 2010
- |||| taspoglutide (BIM51077) / Ipsen
Trial primary completion date: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone. (clinicaltrials.gov) - Jul 28, 2016
P3, N=326, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2011 --> Apr 2010 Trial primary completion date: Mar 2011 --> Nov 2010
- |||| taspoglutide (BIM51077) / Ipsen
Trial primary completion date: A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes (clinicaltrials.gov) - Dec 25, 2014
P3, N=756, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2011 --> Nov 2010 Trial primary completion date: Mar 2011 --> Nov 2010
- ||||| Byetta (exenatide) / AstraZeneca, taspoglutide (BIM51077) / Ipsen
Trial initiation date: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both. (clinicaltrials.gov) - Apr 22, 2013
P3, N=1189, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2011 --> Nov 2010 Initiation date: Oct 1900 --> Jul 2008
- ||||||| taspoglutide (BIM51077) / Ipsen
Trial completion: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise. (clinicaltrials.gov) - Jul 4, 2012
P3, N=373, Completed, Sponsor: Hoffmann-La Roche
Initiation date: Oct 1900 --> Jul 2008 Active, not recruiting --> Completed
- ||||||| taspoglutide (BIM51077) / Ipsen
Trial completion: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone. (clinicaltrials.gov) - Jul 4, 2012
P3, N=326, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Januvia (sitagliptin) / Merck (MSD), taspoglutide (BIM51077) / Ipsen
Trial completion: A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin. (clinicaltrials.gov) - Oct 16, 2011
P3, N=666, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| taspoglutide (BIM51077) / Ipsen
Trial completion, Combination therapy: A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea. (clinicaltrials.gov) - Oct 13, 2011
P3, N=1072, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Byetta (exenatide) / AstraZeneca, taspoglutide (BIM51077) / Ipsen
Trial completion: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both. (clinicaltrials.gov) - Oct 13, 2011
P3, N=1189, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed